Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO

During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) vs rituximab (R)-GemOx in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). The discussion was preceded by a presentation by Gareth Gregory, chaired by Gilles Salles, and featured Ulrich Jäger, Francesc Bosch, Michael Dickinson, Astrid Pavlovsky, Marek Trněný, Alison Moskowitz, and Stefano Luminari. Gregory presented an overview of the STARGLO trial, efficacy and safety data, and key takeaways. This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.